CJun NH2-terminal kinase 1 (JNK1): Roles in metabolic regulation of insulin resistance

Trends in Biochemical Sciences

Volumn 35, Issue 9, 2010, Pages 490-496

  Sabio, Guadalupe ^a   Davis, Roger J ^b  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; LIPOPROTEIN LIPASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; PROTIRELIN; STRESS ACTIVATED PROTEIN KINASE 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; THYROTROPIN; TRIACYLGLYCEROL;

ADIPOSE TISSUE; BONE MARROW CELL; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; ENERGY EXPENDITURE; FATTY LIVER; GENE EXPRESSION REGULATION; GLUCOSE HOMEOSTASIS; HORMONE SYNTHESIS; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; METABOLIC REGULATION; METABOLIC SYNDROME X; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; ANIMAL; DIET; HUMAN; METABOLISM; MOUSE;

MUS;

ANIMALS; DIET; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 8; OBESITY;

EID: 77956185248     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2010.04.004     Document Type: Review

References (70)

1. Bastard J.P., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 2006, 17:4-12.
2. Zimmet P., et al. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
3. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997, 46:3-10.
4. Shoelson S.E., et al. Inflammation and insulin resistance. J. Clin. Invest. 2006, 116:1793-1801.
5. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
6. White M.F. Insulin signaling in health and disease. Science 2003, 302:1710-1711.
7. Weston C.R., Davis R.J. The JNK signal transduction pathway. Curr. Opin. Cell Biol. 2007, 19:142-149.
8. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103:239-252.
9. Hirosumi J., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
10. Tuncman G., et al. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10741-10746.
11. Kaneto H., et al. Oxidative stress and the JNK pathway as a potential therapeutic target for diabetes. Drug News Perspect. 2004, 17:447-453.
12. Nakatani Y., et al. Modulation of the JNK pathway in liver affects insulin resistance status. J. Biol. Chem. 2004, 279:45803-45809.
13. Bennett B.L., et al. JNK: a new therapeutic target for diabetes. Curr. Opin. Pharmacol. 2003, 3:420-425.
14. Kaneto H., et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat. Med. 2004, 10:1128-1132.
15. Stebbins J.L., et al. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16809-16813.
16. Tournier C., et al. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev. 2001, 15:1419-1426.
17. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140:900-917.
18. Hotamisligil G.S. Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int. J. Obes. (Lond.) 2008, 32(Suppl. 7):S52-S54.
19. Nakamura T., et al. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 2010, 140:338-348.
20. Tsukumo D.M., et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007, 56:1986-1998.
21. Shi H., et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 2006, 116:3015-3025.
22. Jaeschke A., Davis R.J. Metabolic stress signaling mediated by mixed-lineage kinases. Mol. Cell 2007, 27:498-508.
23. Jaeschke A., et al. An essential role of the JIP1 scaffold protein for JNK activation in adipose tissue. Genes Dev. 2004, 18:1976-1980.
24. Uysal K.T., et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610-614.
25. Sabio G., et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322:1539-1543.
26. Sabio G., et al. Role of muscle c-Jun NH2-terminal kinase 1 in obesity-induced insulin resistance. Mol. Cell Biol. 2010, 30:106-115.
27. Aguirre V., et al. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol. Chem. 2000, 275:9047-9054.
28. Lee Y.H., et al. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J. Biol. Chem. 2003, 278:2896-2902.
29. Aguirre V., et al. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem. 2002, 277:1531-1537.
30. Copps K.D., et al. Irs1 serine 307 promotes insulin sensitivity in mice. Cell Metab. 2010, 11:84-92.
31. Tanti J.F., Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr. Opin. Pharmacol. 2009, 9:753-762.
32. Giraud J., et al. Phosphorylation of Irs1 at SER-522 inhibits insulin signaling. Mol. Endocrinol. 2007, 21:2294-2302.
33. Luo M., et al. Phosphorylation of human insulin receptor substrate-1 at Serine 629 plays a positive role in insulin signaling. Endocrinology 2007, 148:4895-4905.
34. Luo M., et al. Identification of insulin receptor substrate 1 serine/threonine phosphorylation sites using mass spectrometry analysis: regulatory role of serine 1223. Endocrinology 2005, 146:4410-4416.
35. Yi Z., et al. Global assessment of regulation of phosphorylation of insulin receptor substrate-1 by insulin in vivo in human muscle. Diabetes 2007, 56:1508-1516.
36. Hoehn K.L., et al. IRS1-independent defects define major nodes of insulin resistance. Cell Metab. 2008, 7:421-433.
37. Das M., et al. Induction of hepatitis by JNK-mediated expression of TNF-alpha. Cell 2009, 136:249-260.
38. Vallerie S.N., et al. A predominant role for parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity. PLoS One 2008, 3:e3151.
39. Solinas G., et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab. 2007, 6:386-397.
40. Ogawa W., Kasuga M. Cell signaling. Fat stress and liver resistance. Science 2008, 322:1483-1484.
41. Odegaard J.I., et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
42. Kang K., et al. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 2008, 7:485-495.
43. Nguyen M.T., et al. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J. Biol. Chem. 2005, 280:35361-35371.
44. Kim T., et al. Knockdown of JNK rescues 3T3-L1 adipocytes from insulin resistance induced by mitochondrial dysfunction. Biochem. Biophys. Res. Commun. 2009, 378:772-776.
45. Rozo A.V., et al. Silencing Jnk1 and Jnk2 accelerates basal lipolysis and promotes fatty acid re-esterification in mouse adipocytes. Diabetologia 2008, 51:1493-1504.
46. Emanuelli B., et al. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J. Biol. Chem. 2000, 275:15985-15991.
47. Rui L., et al. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 2002, 277:42394-42398.
48. Mooney R.A., et al. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J. Biol. Chem. 2001, 276:25889-25893.
49. Senn J.J., et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 2003, 278:13740-13746.
50. Emanuelli B., et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J. Biol. Chem. 2001, 276:47944-47949.
51. Mooney R.A. Counterpoint: interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 2007, 102:816-818. discussion 818-819.
52. Pedersen B.K., Febbraio M.A. Point: interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 2007, 102:814-816.
53. Inoue H., et al. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 2006, 3:267-275.
54. Wallenius V., et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 2002, 8:75-79.
55. Klover P.J., et al. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003, 52:2784-2789.
56. Kim H.J., et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004, 53:1060-1067.
57. Klover P.J., et al. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005, 146:3417-3427.
58. Torisu T., et al. The dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells 2007, 12:143-154.
59. Savage D.B., et al. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 2007, 87:507-520.
60. Vijayvargia R., et al. JNK deficiency enhances fatty acid utilization and diverts glucose from oxidation to glycogen storage in cultured myotubes. Obesity 2010, 10.1038/oby.2009.501.
61. Morino K., et al. Muscle-specific IRS-1 Ser->Ala transgenic mice are protected from fat-induced insulin resistance in skeletal muscle. Diabetes 2008, 57:2644-2651.
62. Wang H., et al. Skeletal muscle-specific deletion of lipoprotein lipase enhances insulin signaling in skeletal muscle but causes insulin resistance in liver and other tissues. Diabetes 2009, 58:116-124.
63. Yang R., et al. Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor gamma coactivator 1 beta and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice. J. Biol. Chem. 2007, 282:22765-22774.
64. Emanuelli B., et al. Overexpression of the dual-specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3545-3550.
65. Sabio G., et al. Prevention of steatosis by hepatic JNK1. Cell Metab. 2009, 10:491-498.
66. Lenard N.R., Berthoud H.R. Central and peripheral regulation of food intake and physical activity: pathways and genes. Obesity 2008, 16(Suppl. 3):S11-S22.
67. Sabio G., et al. Role of the hypothalamic-pituitary-thyroid axis in metabolic regulation by JNK1. Genes Dev. 2010, 24:256-264.
68. Belgardt B.F., et al. Hypothalamic and pituitary c-Jun N-terminal kinase 1 signaling coordinately regulates glucose metabolism. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6028-6033.
69. Kaneto H., et al. Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid. Redox Signal. 2007, 9:355-366.
70. Ijaz A., et al. Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes. Kidney Int. 2009, 75:381-388.